Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Mirvetuximab soravtansine by AbbVie for Endometrial Cancer: Likelihood of Approval
Mirvetuximab soravtansine is under clinical development by AbbVie and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...